We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I am going to try and watch it. They need to restore confidence..
2pm is CEO and CFO online presentation relating to the trading update.
I'll be keen to see what impression that makes on any who are able to attend and feedback.
4P today. Fill yer boots!
Rally time
Key line for me - Previously reported Group financials including revenues, net revenues per Accrufer® prescription, and compliance with financial covenants on the Group's debt instrument are not affected by this change
500,000 shares
It is a no brainer
Rising sales {if below forcasts so what]
Excellent sales price
Popular and needed medical product
BEST OF AT AN ALL TIME LOW
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and expanded sales team are “bearing fruit”, according to analysts.
Accrufer is a non-salt based oral therapy used to treat iron deficiency in adults.
Analysts at Cavendish said key performance indicators such as total scrips, new scrips, retention rate, and net realised price are all showing significant improvement compared to the first half of 2023.
The number of US representatives promoting Accrufer increased from 16 to 30 in the first quarter of 2023, and by May 2023, a total of 100 had been trained to sell the product.
Third quarter unaudited sales were US$4.1 million, above the broker’s forecasts of US$3.6 million, and the company said trading is in-line with expectations.
Link: https://www.proactiveinvestors.co.uk/companies/news/1036099/shield-therapeutics-is-bearing-fruit-says-cavendish-1036099.html
Just spotted another £84k buy at 2.82 just before close.
Date Time Trade Prc Volume Buy/Sell Value
21-Feb-24 16:24:37 2.825 3,000,000 84.75k
I expect we will see another Rns in the next few days, I am sure the insider’s will be busy buying again at these prices.
London, UK, 27 November 2023: Shield Therapeutics plc
(LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), confirms that Mr Hans Peter Hasler, Chairman, acquired 2,000,000 Ordinary Shares in the Company on 21 November 2023 at a price of 6.1p per share. Mr Hasler now holds a beneficial interest in 5,500,000 Ordinary Shares.
Harchris good post mate. Cash call coming soon, a big one at a deep discount
Sharemeister & fundamental analysis........I see your new here & have absolutely no understanding of STX & the way this share behaves & the way its pumped & dumped.
Do any of you 2 know hiw many fund raises there gas been & the price of them. A little proper research might give you a different understanding and not ost the usual nonsense.
Thank you 404.
I note from today’s RNS that Q2 23 produced 14.9k sales at circa 20% less selling price, so I estimate the revenue was 1.8m. Obviously licensing money/deals are presumably taken as revenue and cash (when received)
The revenue requirement of the covenant is on a trailing 4 quarter basis, up to including Q1 totalling $22.5m. They didn't report Q2 23 revenue separately which would be necessary to add to the Q3+Q4 numbers they did provide to see where they're up to.
Given we're already more than half way through the quarter and RNS today assumption has to be they're not at risk of a revenue related breach as early as Q1 fwiw. If anything the minimum cash component of the covenant arguably more in play. Where it gets dicey is that revenue requirement increasing dramatically as the year goes on.
In order Not to breach lending covenant requirements, what revenue/prescriptions do we need to achieve in Q1? As far as I can see from info available, it looks like around 30-34k prescriptions required. Can any concur or offer a number?
Best case scenario IMO is a DNL-type 'arrangement'. For those who may remember that quite frankly dubious-looking play.
Still, I expect we will see absolutely huge inside buying RNS's at 7am, right? Especially from our illustrious CEO, whose enthusiastic words never quite seem to translate into actual...well actions :)
It will get taken out shortly. This is chump change for Viatris and they could take it out for less than they are committed to pay by 2025 anyway. No brainer...
Nonsense, trust is well and truly shot now. STX need two things to be successful, prescription growth to match or at least come close to the projections from 2023 through to 2025 and for the average net selling price to increase substantially.
Results on the prescription side were as bad as it could possibly be. Having intimated that (revised) guidance would be met that left us expecting 50000 prescriptions but understanding if it falls just short, at say low 40s... 22000 is appealing considering this was when the full salesforce were trained up and ready to really accelerate sales.
If there was a sign that the average net selling price was going in the right direction that would at least offer a ray of light but having been informed of a $148 price in Q3 the total of $145 for H2 is in the wrong direction.
Could they still get back on track and end up turning things around for those still holding? Sure, it's possible but it's looking rather unlikely to me. Big cash raise comes next and that will bring the potential upside right down even if they were to execute better going forward.
1 ,3, 7, & 10 Million Share trades!! Somebody is loading up! Share price is a joke atm cheap as chips.
Herd will arrive tomorrow.
That's total BS. Buy volume today says it all! Fall totally overdone big bounce back tomorrow.
Didn't warrant a 50% drop it actually wasn't that bad, I will be buying shed loads in the morning before the bargain hunter herd arrives.
Trust in management now gone completely
£67k buy at 16:35, and a £83k late reported buy from 14.45 @(2.78) it had to be a buy because the sell price was around 2.73 @ 14:45.
Looking good for tomorrow.
Cash burn running at circa $3.3m per month, so they will have to pull something out the bag very soon.
Large buy late in the day @ 3.01p.Hopefully things will improve!
The new CFO is clearing the decks, putting in proper cost controls, and appears to have got a grip on things.
Provided the audited annual results in April don't rock the boat, this could now be one of the most underrated stocks on AIM.
There should be finance backers if needed to come in even at a higher sp than today!